Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1373/jalm.2018.028290 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New cardiovascular biomarkers in patients with advanced cancer - A prospective study comparing MR-proADM, MR-proANP, copeptin, high-sensitivity troponin T and NT-proBNP.
Eur J Heart Fail
November 2024
Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.
Article Synopsis
- Traditional cardiovascular biomarkers like hsTnT and NT-proBNP are crucial for monitoring cardiac function and prognosis in cancer patients, but newer biomarkers such as MR-proADM, copeptin, and MR-proANP may provide better predictive power.
- A study involving 442 hospitalized cancer patients showed that while several biomarkers predicted all-cause mortality, only MR-proADM remained a significant independent predictor after adjusting for various factors.
- MR-proADM demonstrated the highest predictive accuracy, with a specific cutoff of 0.94 nmol/L signaling a higher risk of mortality, particularly in older patients with advanced cancer stages and poorer overall health.
MR-proANP levels in Acute ischemic stroke and clinical outcomes: a systematic review and meta-analysis.
Neurosurg Rev
November 2024
Department of Neurosurgery and Neurology, Duke University Hospital, Durham, NC, USA.
In patients with acute ischemic stroke, midregional proatrial natriuretic peptide (MR-proANP) has shown promise in preliminary studies for risk stratification. The objective of this study is to evaluate the prognostic utility of MR-proANP in AIS, focusing on its ability to predict 90-day functional outcomes, mortality rates, and the presence of atrial fibrillation (Afib). A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus, following PRISMA guidelines.
View Article and Find Full Text PDFElevated filling pressure of the left ventricle (LV) defines diastolic dysfunction. The gold standard for diagnosis is represented by the measurement of LV end-diastolic pressure (LVEDP) during cardiac catheterization, but it has the disadvantage of being an invasive procedure. This study aimed to investigate the correlation between LVEDP and cardiac serum biomarkers such as natriuretic peptides (mid-regional pro-atrial natriuretic peptide [MR-proANP], B-type natriuretic peptide [BNP], and N-terminal prohormone BNP [NT-proBNP]), soluble ST2 (sST2), galectin-3 and mid-regional pro-adrenomedullin (MR-proAMD).
View Article and Find Full Text PDFInteratrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
Circulation
December 2024
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus (W.T.A.).
Article Synopsis
- An interatrial shunt is being studied as a potential treatment for heart failure, aimed at lowering left atrial pressure and improving symptoms and outcomes for patients.
- In a clinical trial involving 508 patients, participants were randomly assigned to receive either the shunt or a placebo, with their progress tracked over a maximum of two years.
- Results showed that while the shunt had no major safety issues, it did not significantly improve overall effectiveness compared to the placebo, although it appeared to reduce adverse cardiovascular events in patients with reduced left ventricular ejection fraction.
Diabetes mellitus is associated with low exercise capacity and impaired peripheral vasodilation in patients with heart failure - a propensity score-matched study.
Diabetes Res Clin Pract
November 2024
DZHK (German Centre for Cardiovascular Research), partner site Goettingen, Germany; Department of Cardiology an Pneumology, University Medical Center Goettingen, Germany.
Aims: Diabetes mellitus (DM) and heart failure (HF) share vascular, skeletal and metabolic abnormalities that can reduce exercise capacity. We investigated whether exercise capacity differ in patients with type 2 DM compared to those without DM with HF of similar severity.
Methods And Results: The Studies Investigating Co-morbidities Aggravating HF (SICA-HF) prospectively enrolled 615 patients with chronic HF, 259 (42.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!